BACKGROUND: Quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma has become the standard of care in the management of HIV-infected patients. There are several commercially available assays that have been implemented for the detection of HIV-1 RNA in plasma. Here, the new Hologic Aptima® HIV-1 Quant Dx assay (Aptima HIV) was compared to the Roche COBAS® TaqMan® HIV-1 Test v2.0 for use with the High Pure System (HPS/CTM). METHODS: The performance characteristics of the assays were assessed using commercially available HIV reference panels, dilution of the WHO 3rd International HIV-1 RNA International Standard (WHO-IS) and plasma from clinical specimens. Assay performance was determined by linear regression, Deming correlation analysis and Bland-Altman analysis. RESULTS: Testing of HIV-1 reference panels revealed excellent agreement. The 61 clinical specimens quantified in both assays were linearly associated and strongly correlated. CONCLUSIONS: The Aptima HIV assay offers performance comparable to that of the HPS/CTM assay and, as it is run on a fully automated platform, a significantly improved workflow.
BACKGROUND: Quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma has become the standard of care in the management of HIV-infectedpatients. There are several commercially available assays that have been implemented for the detection of HIV-1 RNA in plasma. Here, the new Hologic Aptima® HIV-1 Quant Dx assay (Aptima HIV) was compared to the Roche COBAS® TaqMan® HIV-1 Test v2.0 for use with the High Pure System (HPS/CTM). METHODS: The performance characteristics of the assays were assessed using commercially available HIV reference panels, dilution of the WHO 3rd International HIV-1 RNA International Standard (WHO-IS) and plasma from clinical specimens. Assay performance was determined by linear regression, Deming correlation analysis and Bland-Altman analysis. RESULTS: Testing of HIV-1 reference panels revealed excellent agreement. The 61 clinical specimens quantified in both assays were linearly associated and strongly correlated. CONCLUSIONS: The Aptima HIV assay offers performance comparable to that of the HPS/CTM assay and, as it is run on a fully automated platform, a significantly improved workflow.
Authors: Christina Yek; Marta Massanella; Tashi Peling; Kristen Lednovich; Sangeetha V Nair; Andrew Worlock; Milenka Vargas; Sara Gianella; Ronald J Ellis; Matthew C Strain; Michael P Busch; C Thomas Nugent; Douglas D Richman Journal: J Clin Microbiol Date: 2017-06-07 Impact factor: 5.948
Authors: Malaya K Sahoo; Vici Varghese; Elizabeth White; Meg Winslow; David A Katzenstein; Robert W Shafer; Benjamin A Pinsky Journal: J Clin Microbiol Date: 2016-08-17 Impact factor: 5.948
Authors: Mark M Manak; Holly R Hack; Sangeetha V Nair; Andrew Worlock; Jennifer A Malia; Sheila A Peel; Linda L Jagodzinski Journal: J Clin Microbiol Date: 2016-08-10 Impact factor: 5.948
Authors: Frank Wiesmann; Robert Ehret; Gudrun Naeth; Martin Däumer; Jörg Fuhrmann; Rolf Kaiser; Christian Noah; Martin Obermeier; Gunnar Schalasta; Carsten Tiemann; Eva Wolf; Heribert Knechten; Patrick Braun Journal: J Clin Microbiol Date: 2018-09-25 Impact factor: 5.948
Authors: Clara A Agutu; Caroline J Ngetsa; Matt A Price; Tobias F Rinke de Wit; Gloria Omosa-Manyonyi; Eduard J Sanders; Susan M Graham Journal: PLoS One Date: 2019-06-27 Impact factor: 3.240